Gavi provides funding to partners through the partners’ engagement framework (PEF). This allows them, in turn, to support countries’ immunisation programmes.

Support under PEF is divided into three areas. These are: targeted country assistancestrategic focus areas and foundational support. Most PEF funding is allocated to targeted country assistance.

PEF, which came into force in 2016, marks a significant evolution in the way Alliance partners, particularly WHO and UNICEF, work together. It clarifies the role of each partner, brings countries  together with partners to identify the support they need, and enforces accountability for results.


PEF clearly defines the type of support that each Vaccine Alliance partner provides. It reduces overlaps and leverages the comparative strengths of each partner.


Countries are at the heart of the partner activities funded by PEF. For example, countries themselves identify the technical support they need to overcome key immunisation bottlenecks. Countries also regularly assess the support they receive from partners.

PEF dedicates most of its resources to technical assistance to countries. This is a major shift from Gavi’s previous approach, where activities were largely defined and funded at the global and regional levels.


PEF gives priority to the 20 countries* that face the most severe immunisation challenges. Partner activities funded through PEF aim to meet the specific needs of each country.

*PEF priority countries in 2016 were:  Afghanistan, Chad, Nigeria, Uganda, Pakistan, Indonesia, DRC, India, Kenya, Ethiopia,  Niger, CAR, Myanmar, Haiti, Somalia, Yemen, Mozambique, PNG, Madagascar, South Sudan.


The PEF accountability framework defines key performance indicators for activities at all levels. An example of a country-level indicator is the requirement to reach a certain level of coverage with a newly introduced vaccine.

We monitor progress against all indicators to ensure our investments deliver results.

PEF support areas


Related content

Last updated: 8 Apr 2024

Subscribe to our newsletter